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Background
Patient stratification for therapeutic response mainly focus
on biomarker expression on cancer cells. Contrary, the
tumour micromileu is less considered, although stromal
cells and leukocytes play a crucial role in tumour progres-
sion and drug resistance. The present study investigates
the impact of tumour infiltrating lymphocytes on catu-
maxomab efficacy in CRC.
Patients and methods
Fresh tumour samples from 27 CRC patients were used
to prepare tumour spheroids. Autologous PBMCs were
isolated by ficoll density gradient. Tumour spheroids
co-cultured with or without PBMCs were treated with
catumaxomab for 96h. The cellular composition of the
spheroids and the therapeutic impact on epithelial cells
and leukocytes were measured by FACS analysis. The
metabolic activity of the co-cultures was determined by
the ATP assay.
Results
Similar to their original cancers all spheroid models con-
sisted of a sufficient high fraction of EpCAM positive
tumour cells indicating CRC an appropriate cancer type
for catumaxomab therapy. In contrast, the fraction of
CD45 positive leukocytes in spheroids was low mimicking
the parental tumours. The effector cell to target cell (E:T,
CD45 : EpCAM) ratio ranged from 0,05:1 to 1,92:1. Treat-
ment of these spheroids with catumaxomab revealed no
significant therapeutic effect. Addition of patient specific
PBMCs changed the E:T ratio up to 7:1 and had a signifi-
cant impact on antibody efficacy. Catumaxomab induced
cell death was found up to 52% (p=0,015) depending on
the individual E:T ratio. After catumaxomab treatment
co-cultures demonstrated metabolic stimulation underlin-
ing the functionality of the leukocytes.
Conclusions
A dual biomarker system is required to select appropriate
CRC patients for catumaxomab treatment. EpCAM
expression on cancer cells is required, but the leukocyte
infiltrate is the key predictor for the therapeutic response
of catumaxomab. Both extent and functionality of the
tumour infiltrating leukocytes have to be determined in
the individual tumour sample for targeted therapy using
the trifunctional monoclonal antibody.
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